Overall, as has been observed with all advanced therapies used to treat CD, evidence suggests that therapeutic benefit is maximized if vedolizumab is initiated as a first-line biologic early in the disease course rather than waiting until after other treatments, including anti-TNFα treatments, have failed. This evidence concerns the gene TNF and Cowden disease.